Early-onset T2DM is strongly associated with obesity, metabolic syndrome features, insulin resistance, family history, and necessitates faster progression to insulin therapy, i.e., in 2–5 years after diagnosis in >50% of patients [2]. This evidence concerns the gene INS and Obesity.